BackgroundLiver transplantation is the life‐saving treatment for many end‐stage pediatric liver diseases. The perioperative course, including surgical and anesthetic factors, have an important influence on the trajectory of this high‐risk population. Given the complexity and variability of the immediate postoperative course, there would be utility in identifying risk factors that allow prediction of adverse outcomes and intensive care unit trajectories.AimsThe aim of this study was to develop and validate a risk prediction model of prolonged intensive care unit length of stay in the pediatric liver transplant population.MethodsThis is a retrospective analysis of consecutive pediatric isolated liver transplant recipients at a single institution between April 1, 2013 and April 30, 2020. All patients under the age of 18 years receiving a liver transplant were included in the study (n = 186). The primary outcome was intensive care unit length of stay greater than 7 days.ResultsRecipient and donor characteristics were used to develop a multivariable logistic regression model. A total of 186 patients were included in the study. Using multivariable logistic regression, we found that age < 12 months (odds ratio 4.02, 95% confidence interval 1.20–13.51, p = .024), metabolic or cholestatic disease (odds ratio 2.66, 95% confidence interval 1.01–7.07, p = .049), 30‐day pretransplant hospital admission (odds ratio 8.59, 95% confidence interval 2.27–32.54, p = .002), intraoperative red blood cells transfusion >40 mL/kg (odds ratio 3.32, 95% confidence interval 1.12–9.81, p = .030), posttransplant return to the operating room (odds ratio 11.45, 95% confidence interval 3.04–43.16, p = .004), and major postoperative respiratory event (odds ratio 32.14, 95% confidence interval 3.00–343.90, p < .001) were associated with prolonged intensive care unit length of stay. The model demonstrates a good discriminative ability with an area under the receiver operative curve of 0.888 (95% confidence interval, 0.824–0.951).ConclusionsWe develop and validate a model to predict prolonged intensive care unit length of stay in pediatric liver transplant patients using risk factors from all phases of the perioperative period.

Table 1 outlines VAS pain outcomes as related to the procedure, both preoperative and postoperative. There was a significant difference between improvement of resting pain (2.63 point improvement, <0.000001), as well as a significant difference between improvement of worst pain before and after the SpineJack procedure (1.88 point improvement, <0.0001). Conclusions These results support the safety and efficacy of the SpineJack procedure as related to current conventional treatments in the setting of vertebral fractures.

ConclusionThe Pipeline embolization device is a novel technique that can be utilized for treatment of giant cerebrovascular aneurysms with emerging evidence of immediate and longterm success. Further patient enrollment and clinical trials will be required to assess its efficacy in comparison to other endovascular and surgical approaches for the treatment of giant aneurysms. Disclosures M. Fana: None. O. Alsrouji: None. M. Rehman: None.